Study of the Safety and Immunogenicity of a Novel H5N1 Influenza Vaccine in Healthy Adults Age 18-49

Condition:   InfluenzaIntervention:   Biological: VAX161C vaccineSponsor:   VaxInnate CorporationCompleted - verified March 2015
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials